Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular evidence of neuroinvasive Sindbis virus infection in humans: detection in cerebrospinal fluid by next generation sequencing.

Emerging microbes & infections·2026

Same author

[Lean and Value-Based Healthcare methods to support the chronic heart failure care model.]

Recenti progressi in medicina·2026

Same author

Cryptic severe Plasmodium falciparum malaria in Maremma (Tuscany, Italy), 2024: a case report from a historically receptive area.

Travel medicine and infectious disease·2026

Same author

[Value-Based Healthcare analysis of antibiotic administration in non-hospital settings: assessment of patient benefits and economic sustainability of the system.]

Recenti progressi in medicina·2026

Same author

Dupilumab in Severe Asthma-COPD Overlap: Real-Life Experience on a Case Series.

Journal of personalized medicine·2026

Same author

Beyond Echocardiography: The Evolving Role of Imaging in Left Atrial Appendage Closure in the Modern Era.

Journal of cardiovascular echography·2026

Search research articles

Related Experiment Videos

Mesalazine-induced multi-organ hypersensitivity.

Bruno Sposato¹, Maria Pia Allegri, Maria Piera Riccardi

¹Unità Operativa Pneumologia, Ospedale Misericordia Grosseto, Grosseto, Italy. bsposat@tin.it

Clinical Drug Investigation

|May 6, 2010

Summary

Mesalazine, used for ulcerative colitis, can cause rare multi-organ hypersensitivity. Discontinuing the drug resolved all symptoms in a patient, confirming its adverse effects.

Related Experiment Videos

Area of Science:

Gastroenterology
Clinical Pharmacology
Immunology

Background:

Mesalazine is a common treatment for ulcerative colitis, generally considered safe and effective.
However, isolated reports of mesalazine-induced toxicity affecting various organ systems exist.
These include renal, pancreatic, cardiac, pulmonary, and hematologic adverse events.

Observation:

A patient with ulcerative colitis presented with fever, pericarditis, peripheral eosinophilia, eosinophilic pneumonia, anemia, and hematuria.
These symptoms emerged during mesalazine therapy.
Previous treatments with corticosteroids and antibiotics were ineffective.

Findings:

The patient's symptoms rapidly and completely resolved upon discontinuation of mesalazine.
This strongly suggests mesalazine as the causative agent for the observed multi-organ adverse events.
The presentation included simultaneous eosinophilia and evidence of multi-organ involvement.

Implications:

Mesalazine can induce a hypersensitivity reaction affecting multiple organs.
This potential adverse effect must be considered in patients treated with mesalazine.
Discontinuation of mesalazine is crucial for resolving these hypersensitivity reactions.